Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Achilles Therapeutics (ACHL – Research Report) today and set a price target of $20.00. The company’s shares closed yesterday at $1.79.
Livshits covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Intellia Therapeutics, and Solid Biosciences. According to TipRanks, Livshits has an average return of 24.8% and a 40.24% success rate on recommended stocks.
Achilles Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $20.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $6.88 and a one-year low of $1.72. Currently, Achilles Therapeutics has an average volume of 26.92K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing novel cancer immunotherapies targeting clonal neoantigens. The company has two ongoing trials, the CHIRON trial in patients with advanced non-small cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.
Read More on ACHL:
